Stock Research for CLSN


Featured Broker: Ally Invest

Get the due diligence for another stock.


CLSN Stock Chart & Research Data

The CLSN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CLSN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


CLSN Due diligence Resources & Stock Charts

The CLSN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CLSN Detailed Price Forecast - CNN Money CNN View CLSN Detailed Summary - Google Finance
Yahoo View CLSN Detailed Summary - Yahoo! Finance Zacks View CLSN Stock Research & Analysis -

Stock Analysis

TradeIdeas View CLSN Trends & Analysis - Trade-Ideas Barrons View CLSN Major Holders - Barrons
NASDAQ View CLSN Call Transcripts - NASDAQ Seeking View CLSN Breaking News & Analysis - Seeking Alpha
Spotlight View CLSN Annual Report - OTC Report View CLSN OTC Short Report -
TradeKing View CLSN Fundamentals - TradeKing Charts View CLSN SEC Filings - Bar Chart
WSJ View Historical Prices for CLSN - The WSJ Morningstar View Performance/Total Return for CLSN - Morningstar
MarketWatch View the Analyst Estimates for CLSN - MarketWatch CNBC View the Earnings History for CLSN - CNBC
StockMarketWatch View the CLSN Earnings - StockMarketWatch MacroAxis View CLSN Buy or Sell Recommendations - MacroAxis
Bullish View the CLSN Bullish Patterns - American Bulls Short Pains View CLSN Short Pain Metrics -

Social Media Mentions

StockTwits View CLSN Stock Mentions - StockTwits PennyStocks View CLSN Stock Mentions - PennyStockTweets
Twitter View CLSN Stock Mentions - Twitter Invest Hub View CLSN Investment Forum News - Investor Hub
Yahoo View CLSN Stock Mentions - Yahoo! Message Board Seeking Alpha View CLSN Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for CLSN - Insider Cow View Insider Transactions for CLSN - Insider Cow
CNBC View CLSN Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CLSN - OTC Markets
Yahoo View Insider Transactions for CLSN - Yahoo! Finance NASDAQ View Institutional Holdings for CLSN - NASDAQ

Stock Charts

FinViz View CLSN Stock Insight & Charts - StockCharts View CLSN Investment Charts -
BarChart View CLSN Stock Overview & Charts - BarChart Trading View View CLSN User Generated Charts - Trading View

Latest Financial News for CLSN highlights: Rosehill Resources, Navios Maritime Partners, AMC Entertainment Holdings, Entercom Communications and Celsion
Posted on Friday July 13, 2018 highlights: Rosehill Resources, Navios Maritime Partners, AMC Entertainment Holdings, Entercom Communications and Celsion

5 Cheap Breakout Stocks for Formidable Returns
Posted on Thursday July 12, 2018

The technique seeks to identify stocks whose prices are fluctuating within a specific band.

Posted on Tuesday July 10, 2018

Celsion Corporation (CLSN), an oncology drug development company, today announced that results from a Phase I trial of ThermoDox® were published in the peer-reviewed journal, The Lancet Oncology ¹. Conducted by a multi-disciplinary team of biomedical engineers, oncologists, radiologists and anesthetists at the University of Oxford, United Kingdom, the trial evaluated the safety and efficacy of ThermoDox®, Celsion’s proprietary heat-activated liposomal encapsulation of doxorubicin, along with focused ultrasound for the treatment of liver cancer.

The Week Ahead In Biotech: Delayed Clinical Trial Releases In Focus
Posted on Saturday June 30, 2018

Biotech stocks came under pressure earlier in the week, weighed down by negative trial results, mixed FDA verdicts and overall pessimistic broader market sentiment, but recovered in the last two sessions. ...

Enter a stock symbol to view the stock details.